Amgen Inc. is a biotechnology company dedicated to discovering, developing, manufacturing, and delivering human therapeutics. It focuses on addressing high unmet medical needs to enhance health outcomes and improve lives. Operating primarily in the human therapeutics segment, Amgen's extensive portfolio includes well-known products such as Aranesp, ENBREL, Prolia, Neulasta, Otezla, and Repatha, among others. These therapies target various conditions, showcasing Amgen's commitment to leveraging its expertise in biotechnology to provide innovative solutions for patients. The AMGN YTD return is shown above.
The YTD Return on the AMGN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether AMGN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AMGN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|